These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36857968)

  • 1. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.
    Nambiar A; Kellogg D; Justice J; Goros M; Gelfond J; Pascual R; Hashmi S; Masternak M; Prata L; LeBrasseur N; Limper A; Kritchevsky S; Musi N; Tchkonia T; Kirkland J
    EBioMedicine; 2023 Apr; 90():104481. PubMed ID: 36857968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
    Justice JN; Nambiar AM; Tchkonia T; LeBrasseur NK; Pascual R; Hashmi SK; Prata L; Masternak MM; Kritchevsky SB; Musi N; Kirkland JL
    EBioMedicine; 2019 Feb; 40():554-563. PubMed ID: 30616998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans.
    Zhu Y; Prata LGPL; Gerdes EOW; Netto JME; Pirtskhalava T; Giorgadze N; Tripathi U; Inman CL; Johnson KO; Xue A; Palmer AK; Chen T; Schaefer K; Justice JN; Nambiar AM; Musi N; Kritchevsky SB; Chen J; Khosla S; Jurk D; Schafer MJ; Tchkonia T; Kirkland JL
    EBioMedicine; 2022 Mar; 77():103912. PubMed ID: 35292270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fisetin is a senotherapeutic that extends health and lifespan.
    Yousefzadeh MJ; Zhu Y; McGowan SJ; Angelini L; Fuhrmann-Stroissnigg H; Xu M; Ling YY; Melos KI; Pirtskhalava T; Inman CL; McGuckian C; Wade EA; Kato JI; Grassi D; Wentworth M; Burd CE; Arriaga EA; Ladiges WL; Tchkonia T; Kirkland JL; Robbins PD; Niedernhofer LJ
    EBioMedicine; 2018 Oct; 36():18-28. PubMed ID: 30279143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
    Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
    EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial.
    Li JS; Zhang HL; Guo W; Wang L; Zhang D; Zhao LM; Zhou M
    J Integr Med; 2023 Nov; 21(6):543-549. PubMed ID: 37993378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
    Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
    Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial.
    Yu XQ; Yang SG; Xie Y; Li JS
    J Integr Med; 2020 Mar; 18(2):163-168. PubMed ID: 31928920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin.
    Raffaele M; Kovacovicova K; Frohlich J; Lo Re O; Giallongo S; Oben JA; Faldyna M; Leva L; Giannone AG; Cabibi D; Vinciguerra M
    Cell Commun Signal; 2021 Apr; 19(1):44. PubMed ID: 33832488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.
    Dutta P; Funston W; Mossop H; Ryan V; Jones R; Forbes R; Sen S; Pearson J; Griffin SM; Smith JA; Ward C; Forrest IA; Simpson AJ
    Thorax; 2019 Apr; 74(4):346-353. PubMed ID: 30610155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.